Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02838316Phase 1Active Not Recruiting

Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia

Role: lead

NCT02296528Not ApplicableTerminated

Safety and Efficacy of the Swallow Expansion Device (SED) for Improvement of Swallowing in Patients

Role: lead

NCT07429890Not Yet Recruiting

REVIVE Prospective Registry Cohort Study

Role: lead

All 3 trials loaded